- Home
- ACR vs KOD Comparison
ACR vs KOD Comparison
Compare ACR & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACR
- KOD
- Stock Information
- Founded
- ACR 2005
- KOD 2009
- Country
- ACR United States
- KOD United States
- Employees
- ACR N/A
- KOD N/A
- Industry
- ACR Real Estate Investment Trusts
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACR Real Estate
- KOD Health Care
- Exchange
- ACR Nasdaq
- KOD Nasdaq
- Market Cap
- ACR 121.1M
- KOD 121.5M
- IPO Year
- ACR N/A
- KOD 2018
- Fundamental
- Price
- ACR $15.74
- KOD $2.66
- Analyst Decision
- ACR Buy
- KOD Hold
- Analyst Count
- ACR 1
- KOD 5
- Target Price
- ACR $17.50
- KOD $3.25
- AVG Volume (30 Days)
- ACR 18.1K
- KOD 162.1K
- Earning Date
- ACR 10-30-2024
- KOD 11-12-2024
- Dividend Yield
- ACR N/A
- KOD N/A
- EPS Growth
- ACR N/A
- KOD N/A
- EPS
- ACR 0.82
- KOD N/A
- Revenue
- ACR $76,816,000.00
- KOD N/A
- Revenue This Year
- ACR N/A
- KOD N/A
- Revenue Next Year
- ACR $1.76
- KOD N/A
- P/E Ratio
- ACR $19.17
- KOD N/A
- Revenue Growth
- ACR 13.82
- KOD N/A
- 52 Week Low
- ACR $6.62
- KOD $1.37
- 52 Week High
- ACR $16.13
- KOD $7.77
- Technical
- Relative Strength Index (RSI)
- ACR 55.89
- KOD 52.94
- Support Level
- ACR $15.60
- KOD $2.50
- Resistance Level
- ACR $15.87
- KOD $2.80
- Average True Range (ATR)
- ACR 0.26
- KOD 0.18
- MACD
- ACR -0.01
- KOD 0.01
- Stochastic Oscillator
- ACR 64.08
- KOD 64.71
About ACR ACRES Commercial Realty Corp.
ACRES Commercial Realty Corp is a commercial real estate investment trust that focuses on originating, holding and managing commercial real estate (CRE) mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. The company invests in commercial real-estate-related assets, including whole loans, A notes, B notes, mezzanine loans, and mortgage-related securities, as well as commercial finance assets, which include other asset-backed securities, senior secured corporate loans, equipment leases and notes, trust preferred securities, debt tranches of collateralize debt obligations, and private equity investments mainly issued by financial institutions.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.